Latest Breaking News On - Term treatment with first line ocrelizumab - Page 1 : comparemela.com

Nearly half of 757 relapsing MS patients given Ocrevus early in disease course had no evidence of disease activity 9 years out, study finds.

United statesRobert bermelUniversity of minhoAmerican academy of neurologyAmerican academyTerm treatment with first line ocrelizumabPatients with earlyCleveland clinicDisease activity overOcrelizumab therapyExpanded disability status scale